Initial Resuscitation for Acute Kidney Injury in Cirrhosis

Description

The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a Volume Assessment Guidance Algorithm (VAGA) or give standard of care doses of IV albumin? Patients will be randomly assigned where their treating teams will receive a VAGA-based recommendation or a standard of care IV albumin recommendation.

Conditions

Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome

Study Overview

Study Details

Study overview

The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a Volume Assessment Guidance Algorithm (VAGA) or give standard of care doses of IV albumin? Patients will be randomly assigned where their treating teams will receive a VAGA-based recommendation or a standard of care IV albumin recommendation.

Initial Resuscitation for Acute Kidney Injury in Patients With Cirrhosis: A Pilot Randomized Trial Using a Volume Assessment Guidance Algorithm

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

Condition
Cirrhosis, Liver
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult age 18 years or greater
  • 2. Signed informed consent form (ICF) by any subject capable of giving consent, or, when the subject is not capable of giving consent, by their legally authorized representatives prior to initiation of any study procedures.
  • 3. Admitted to the hospital
  • 4. Diagnosis of decompensated cirrhosis (either prior to admission or new diagnosis on admission).
  • 5. Presence of acute kidney injury (AKI) as defined by International Club of Ascites (ICA) criteria, defined as SCr increase of ≥0.3 mg/dL within 48 hours or ≥50% increase from baseline which is known or presumed to have occurred within the prior 7 days.
  • 1. Requiring \>2 liters (L) supplemental oxygen at the time of screening.
  • 2. In shock requiring vasopressors (vasoconstrictors for the treatment of AKI such as terlipressin, midodrine, and octreotide are allowed).
  • 3. Allergy or other contraindication to IV albumin administration.
  • 4. Death, liver transplant, or renal replacement therapy (RRT) expected within 48 hours.
  • 5. Patient and/or legally authorized representative unable to provide informed consent.
  • 6. Hepatic encephalopathy grade 3 or 4 at the time of screening.
  • 7. Already received \>200 g albumin during admission at the time of screening.
  • 8. Severe, active bleeding requiring 3 or more units of red blood cell transfusion in the 48 hours prior to screening.
  • 9. Admission to the intensive care unit at the time of screening.
  • 10. Mechanical ventilation at the time of screening.
  • 11. Presence of New York Heart Association (NYHA) class 3-4 symptoms of congestive heart failure at the time of screening.
  • 12. History of prior liver or kidney transplant.
  • 13. Pregnant or nursing status
  • 14. Any condition, in the opinion of the investigator, that could confound or interfere with the safe completion of study activities.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Study Record Dates

2026-03